Daniel Costa
Scholarship Advisor, Medical Oncology · Beth Israel Deaconess Medical Center
Credentials: · · · ·
History
- 2003–2005
Medical Oncology
- 2000–2003
Internal Medicine
- 1996–2000
Doctor of Medicine
Research
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
New England Journal of Medicine · 2010 · 3,649 citations
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
Journal of Clinical Oncology · 2009 · 1,584 citations
Crizotinib in ROS1-rearranged non-small-cell lung cancer
New England Journal of Medicine · 2014 · 1,560 citations
59 papers
52 papers · 4 as a fellow
- MH
31 papers
17 papers
13 papers · 3 as a fellow
13 papers · 12 as a fellow
- DT
12 papers
10 papers
Grants
- 2022–2027
Dana Farber/Harvard Cancer Center SPORE in Lung Cancer
National Cancer Institute · P50
Project lead · $483.1K · Dana-Farber Cancer Inst
- 2018–2025
Unmet Needs for Specific Subsets of EGFR Mutated Lung Cancer
National Cancer Institute · R37
Contact PI · $2.8M · Beth Israel Deaconess Medical Center